Dusa completes enrollment for Phase IIb acne trial

The study’s objective is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy (PDT) treatments with Levulan Kerastick in combination with BLU-U brand blue light versus use of the BLU-U alone in patients with moderate to severe facial acne vulgaris. This trial will evaluate the incremental advantage of adding Levulan to Dusa’s already FDA-cleared BLU-U blue light therapy when treating acne.

Bob Doman, president and CEO of Dusa, said: “Once the initial results are available, which we expect this fall, company will decide on the next steps needed to develop this indication for potential FDA approval.”